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Abstract
Background: Pancreatic cancer has a 5-year survival rate of only 5–7%. Difficulties in detecting pancreatic cancer at
early stages results in the high mortality and substantiates the need for additional diagnostic tools. Surgery is the
only curative treatment and unfortunately only possible in localized tumours. A diagnostic biomarker for pancreatic
cancer will have a major impact on patient survival by facilitating early detection and the possibility for curative
treatment. DNA promoter hypermethylation is a mechanism of early carcinogenesis, which can cause inactivation of
tumour suppressor genes. The aim of this study was to examine promoter hypermethylation in a panel of selected
genes from cell-free DNA, as a diagnostic marker for pancreatic adenocarcinoma.
Methods: Patients with suspected or biopsy-verified pancreatic cancer were included prospectively and
consecutively. Patients with chronic/acute pancreatitis were included as additional benign control groups. Based on
an optimized accelerated bisulfite treatment protocol, methylation-specific PCR of a 28 gene panel was performed
on plasma samples. A diagnostic prediction model was developed by multivariable logistic regression analysis using
backward stepwise elimination.
Results: Patients with pancreatic adenocarcinoma (n = 95), chronic pancreatitis (n = 97) and acute pancreatitis (n =
59) and patients screened, but negative for pancreatic adenocarcinoma (n = 27), were included. The difference in
mean number of methylated genes in the cancer group (8.41 (95% CI 7.62–9.20)) vs the total control group (4.74
(95% CI 4.40–5.08)) was highly significant (p < 0.001). A diagnostic prediction model (age >65, BMP3, RASSF1A, BNC1,
MESTv2, TFPI2, APC, SFRP1 and SFRP2) had an area under the curve of 0.86 (sensitivity 76%, specificity 83%). The
model performance was independent of cancer stage.
Conclusions: Cell-free DNA promoter hypermethylation has the potential to be a diagnostic marker for pancreatic
adenocarcinoma and differentiate between malignant and benign pancreatic disease. This study brings us closer to
a clinical useful diagnostic marker for pancreatic cancer, which is urgently needed. External validation is, however,
required before the test can be applied in the clinic.
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Background
Pancreatic cancer is the fourth leading cause of cancer
death in the world [1], with a 5-year survival rate of ap-
proximately 5–7% [1, 2]. The only curative treatment is
complete tumour resection. Unfortunately, only 10–20%
of patients receive treatment with the intend to cure. Des-
pite surgery, 50% of patients experience recurrence [3].
Difficulties in detecting the disease at an early stage results
in high mortality. This is mainly due to lacking or non-
specific symptoms, which are also related to chronic pan-
creatitis, an essential differential diagnosis and a known
risk factor for pancreatic cancer [3, 4]. Often, several com-
plex or invasive techniques such as PET scan (positron
emission tomography), CT scan (computed tomography),
endoscopic or laparoscopic ultrasound and ERCP (endo-
scopic retrograde cholangiopancreatography) are needed
for the diagnosis and many patients also need a histo-
logical evaluation. However, the differentiation between
malignant and benign pancreatic disease can be difficult,
and even surgery may be needed to establish a definite
diagnosis. The only useful biomarker is CA-19-9, which is
unspecific as patients with chronic pancreatitis and par-
ticularly benign biliary obstruction tend to express high
levels of CA-19-9. Moreover, 10% of the population lack
the ability to produce CA-19-9, making its utility less ap-
parent [5–7]. It would be a major advance for the patients
if a blood-based diagnostic marker was available.
During the development of pancreatic cancer, genetic
and epigenetic changes take place. Epigenetic modifica-
tions occur at a genomic level, which does not change
the DNA sequence. Epigenetic modifications change the
DNA conformation and therefore the gene expression.
DNA hypermethylation is an epigenetic phenomenon,
where a methyl (CH3) residue is added to cytosines pre-
ceding guanosines (CpGs) [8–11]. Hypermethylation in
the promoter region results in gene silencing, which
may be associated with cancer formation [8, 9, 12, 13].
Cancer cells may release cell-free DNA into the blood
[14, 15]. DNA hypermethylation can be detected in cell-
free DNA in plasma and serum and is potentially
tumour specific and useable as blood-based diagnostic
markers for pancreatic cancer [14–16].
Thus far, only a few studies with small numbers of pa-
tients have evaluated cell-free DNA hypermethylation as a
blood-based marker for pancreatic cancer, testing the
methylation status of only a single gene or small gene
panel [16]. These data have shown a significant difference
in DNA hypermethylation between patients with pancre-
atic cancer and healthy controls [4, 17]. However, the
studies had difficulties in differentiating between malig-
nant and benign pancreatic disease [4]. None of the previ-
ously examined genes have the potential to serve as an
individual diagnostic marker [16]. When developing and
testing a biomarker for pancreatic cancer, inclusion of
relevant control groups with benign pancreatic disease is
very important to enable differentiation of pancreatic
cancer-specific hypermethylation and hypermethylation
related to pancreatic disease in general [16].
The aim of this study was to test (by methylation-
specific polymerase chain reaction (PCR)) cell-free DNA
promoter hypermethylation of a panel of 28 genes as a
blood-based diagnostic marker for pancreatic adenocar-
cinoma, including clinical relevant control groups of pa-
tients with benign pancreatic disease.
Methods
Study design
This study was conducted as a prospective observational
cohort study of patients with suspected or biopsy-verified
pancreatic cancer admitted to the Department of Gastro-
intestinal Surgery, Aalborg University Hospital between
February 2008 and February 2011 [18]. Additional benign
control groups were patients with chronic pancreatitis
treated at the hospital or at the outpatient clinic at Aalborg
University Hospital between August 2013 and August 2014
and patients admitted with acute pancreatitis at the Depart-
ment of Gastrointestinal Surgery, Aalborg University Hos-
pital or the Department of General Surgery, Hospital of
Vendsyssel between November 2013 and May 2015.
The study was approved by the Research Ethics Com-
mittee for the North Denmark Region (N-2013037) and
registered in ClinicalTrials.gov (NCT02079363). All par-
ticipants gave written informed consent.
Participants
Consecutive patients with suspected or biopsy-verified
upper gastrointestinal cancer were included prospectively
in a study on gastrointestinal cancer and venous thrombo-
embolism [18]. Patients had blood drawn on admission
before diagnostic work-up and before any treatment. Pa-
tients were divided into the following groups (Fig. 1a).
Only patients with pancreatic adenocarcinoma (cancer
group) and patients screened, but negative for upper
gastrointestinal cancer (control group 1), were included in
this study. Patients with chronic pancreatitis (control
group 2) had blood drawn during hospitalization or at a
scheduled visit in the outpatient clinic. Patients diagnosed
with acute pancreatitis (control group 3) were enrolled
during the first three days of hospitalization. Patients with
chronic pancreatitis and acute pancreatitis were excluded
if they had previous cancer history or ongoing anticoagu-
lant therapy.
Blood sampling and analytical method
Blood samples were obtained by skilled technicians, using
peripheral venipuncture from an antebrachial vein, ac-
cording to the guidelines recommended by the European
Concerted Action on Thrombosis [19]. EDTA plasma
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samples for methylation analysis were centrifuged for
20 min at 4000 rpm at 4 °C and stored within 2 h after
sampling in a biobank at −80 °C until methylation
analysis.
All methylation analyses were performed by a single
expert laboratory scientist.
Extraction and deamination
Plasma nucleic acids were extracted using the EasyMag
platform (Biomerieux) according to manufacturer’s in-
struction. Approximately 500-μl EDTA plasma was used
for the extraction, and purified nucleic acids were eluted
in 35-μl elution buffer (Biomerieux). Five microliters was
used for quantitation of extracted DNA, and the remain-
der was deaminated as previously described by our
group [20]. In brief, 30-μl DNA extract was mixed with
60-μl deamination solution and deaminated for 10 min
at 90 °C, followed by purification using EasyMag and
elution in 25 μl 10 mM KOH [20].
First round of PCR amplification
In order to amplify the amount of deaminated DNA of
interest, a first round of PCR was conducted using a mix
of outer methylation-specific primers (Additional file 1)
for all promoter regions tested. The reaction buffer for
each sample consisted of 25 μl containing PCR stock,
13 μM MgCl2, 0.6 mM dNTP, 250 nM of each outer pri-
mer (Additional file 1), 1.5 U Taq polymerase (Bioline)
and 0.3 U UNG (Invitrogen). The first round reaction
mix was distributed to individual 200-μl PCR tubes and
incubated for 5 min at 37 °C (UNG activity), followed by
incubation at 95 °C for 5 min and cooling to room
temperature. Twenty-five microliters of purified deamin-
ation product was added to each tube containing the
first round reaction mix. PCR was performed for 20 cy-
cles at 92 °C for 15 s, 55 °C for 30 s and 72 °C for 30 s.
Second round of PCR
Ten microliters of mix containing 0.4 μM inner
methylation-specific primers and methylation-specific
probes (Additional file 1) was distributed in 30 individ-
ual wells in a 96-well PCR plate. Ten microliters of first
round PCR product was added to 710 μl of reaction mix
containing PCR stock, 250 μM dNTP, 10 μM MgCl2,
and 15 U Taq polymerase (Bioline). Twenty microliters
of the reaction mix was added to each of the 30 wells
containing primers and probes. Real-time PCR was car-
ried out for 45 cycles at 94 °C for 15 s, 55 °C for 30 s




Fig. 1 Flow diagram of patients included in the study. a Inclusion of
patients with pancreatic adenocarcinoma. b Inclusion of patients
with chronic pancreatitis. c Inclusion of patients with
acute pancreatitis
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Gene panel
Twenty-eight genes were selected for methylation ana-
lysis (Additional file 2). The genes were primarily se-
lected based on a literature review performed by our
group prior to this study [16]. The genes selected for the
panel had previously been detected as hypermethylated
in either cell-free DNA in plasma or serum, pancreatic
juice or tumour tissue from patients with pancreatic
cancer and in addition unmethylated in samples from
healthy individuals. Few additional genes were chosen
based on a pilot study on cell-free DNA hypermethyla-
tion in colorectal adenocarcinoma (unpublished data).
Primer and probe design
All primers and probes were designed using Beacon De-
signer® (PREMIER Biosoft International, Palo Alto, CA)
software and evaluated to be hypermethylation specific
by MethPrimer® (The Li Lab, Peking, China) [21].
Primers were designed to be rich in CpGs and to be lo-
cated up-stream of exon one, which was interpreted as
the promoter regions of the genes. The aim was to de-
sign PCR products with a length less than 140–150 base
pairs, because the cell-free DNA fragments most likely
have a length of 160 base pairs consistent with nucleo-
somal DNA size [22]. The primers and probes were de-
signed and optimized for the present study; however,
effort was made to design primers for previously tested
promoter sequences (Additional file 1).
Hemi-methylated MEST transcript variant 1 was used
as reference gene in both the first and second round
PCR.
Outcome
The primary aim was to establish a prediction model for
pancreatic adenocarcinoma, enabling differentiation of
pancreatic adenocarcinoma patients and a clinical rele-
vant control group of patients screened, but negative for
upper gastrointestinal cancer and patients with chronic
pancreatitis.
Statistical methods
Each gene in the gene panel was analysed as a binary
variable (hypermethylated or non-methylated).
Validation of dichotomous data
We calculated the differences between the threshold
cycle (Ct) values of the hemimethylated reference gene
MEST transcript variant 1 and the Ct values of each
gene for which Ct > 0 (Δ Ct). To assess the amount of
information lost in the dichotomization, histograms of Δ
Ct for the cancer group and control group 1 combined
with control group 2 were produced.
Level of cell-free DNA
We calculated the median level (ng/ml) of cell-free DNA
for each group. Nonparametric Wilcoxon rank sum test
was used for comparison of the cancer group and the
benign control groups.
The total number of hypermethylated genes was calcu-
lated for each patient. The Kendall’s rank test was used
for correlation analysis of total number of hypermethy-
lated genes and level of cell-free DNA.
Hypermethylated genes
The methylation frequency of each gene and the (exact)
95% confidence interval (CI) were calculated for each
group. The mean number of hypermethylated genes in
each group and the 95% CI was calculated. The means
were compared as numerical data with the nonparamet-
ric Wilcoxon rank sum test. p values less than 0.05 were
considered statistically significant.
Prediction model development
1. Screening of each individual variable as a diagnostic
marker for pancreatic adenocarcinoma: Logistic
regression was performed separately for each gene in the
gene panel and for smoking status, gender and patient
age >65. The p value and the area under the receiver
operating characteristic curve (AUC) were calculated.
2. The selection of variables: Variables having a p value
less than 0.2 were selected for further analysis.
3. Model selection: Stepwise backward elimination in
logistic regression models was performed to select the
relevant variables using 0.05 as the significance level for
removal from the model. In the backward elimination
algorithm, variables were eliminated one by one to
identify the optimal combination of variables
representing the highest predictive power. The least
significant variable in the variable combination was
eliminated in the stepwise procedure. For each
intermediate model, the AUC value was calculated.
4. Determination of the best model: The decision was
based on the model complexity combined with the
model performance according to the AUC.
5. Interactions between the variables: The significance
of interactions between all pairs of variables was
assessed in the final model. Interactions with a p value
less than 0.01 were considered statistically significant.
6. Validation: To account for optimism in the internal
validation of discriminative model performance
(measured by the AUC), “leave pair out cross
validation” was used [23]. For the calibration
performance, Hosmer–Lemeshow test was
performed.
7. Probability score: For each patient, a probability
score was calculated.
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All data were analysed using Stata 14.0 software [Stata-
Corp LP, TX].
All authors had full access to the study data and had
reviewed and approved the final manuscript.
Results
Ninety-five patients with confirmed pancreatic adeno-
carcinoma were included in the study (Fig. 1a). After
diagnostic work-up (gastroscopy, endoscopic ultrasound,
magnetic resonance (MR) or CT scan), 35 patients with-
out evidence of malignancy were categorized as patients
screened but negative for pancreatic adenocarcinoma
(control group 1). Eight patients were subsequently ex-
cluded from this group (Fig. 1a). Two additional groups
of control patients with benign pancreatic disease were
included. Overall, 103 patients with chronic pancreatitis
(control group 2) and 62 patients with acute pancreatitis
(control group 3) were included. Subsequently, six pa-
tients from control group 2 and three patients from con-
trol group 3 were excluded (Fig. 1b, c). Descriptive data
of the four groups are shown in Table 1.
Validation of the dichotomous data
There was no clear difference in Δ Ct between the can-
cer group and control group 1 combined with control
group 2, which indicated that no significant amount of
information was lost by dichotomizing the genes as
hypermethylated or non-methylated genes regardless of
the observed Ct value. Additional file 3a, b lists the dis-
tribution of Ct values (0, 0–25, 25–30 and >30) for each
gene in within patient group and illustrates a slightly dif-
ference in Ct values between the groups, with a tendency
towards Ct values in the cancer group being lower com-
pared to the benign control groups. However, due to
limited power, the effect of this difference could not be
evaluated in the multivariable logistic regression model;
consequently, we treated hypermethylation as a dichoto-
mised variable.
Level of cell-free DNA
Patients with pancreatic adenocarcinoma had a signifi-
cant higher median level of cell-free DNA (11.60 ng/ml
(range 0.60–957.17)) compared to control group 1 with
6.17 ng/ml (range 1.06–48.43), control group 2 with
2.18 ng/ml (0.11–115.44) and 4.09 ng/ml (range 0.65–
62.42) for control group 3 (Additional file 4). In
addition, the correlation between level of cell-free DNA
and number of hypermethylated genes was statistically
significant with a Kendall’s τ of 0.34 (Additional file 5).
The hypermethylation profile for each patient is illus-
trated on the heat map plot in Additional file 6. The
methylation frequency of each gene is presented in
Table 2. The mean number of methylated genes of the
whole gene panel (28 genes) was 8.41 (95% CI 7.62–
9.20) for the cancer group compared to 4.34 (95% CI
3.85–4.83) for patients with chronic pancreatitis (control
group 2), 4.89 (95% CI 4.07–5.71) for patients screened,
but negative for pancreatic cancer (control group 1) and
5.34 (95% CI 4.76–5.91) for patients with acute pancrea-
titis (control group 3). The difference between the can-
cer group and the three benign control groups was
highly statistically significant (Table 3).
Prediction model development
In the following analyses, we chose to combine control
group 1 and 2, as the combined group has symptoms re-
sembling those of pancreatic cancer, which makes a bio-
marker to distinguish these from pancreatic cancer of
utmost clinical relevance. For the remainder of the ana-
lysis, patients with acute pancreatitis were excluded be-
cause a clinical picture of acute inflammation is rarely
seen in pancreatic cancer.











N 95 27 97 59 124
Mean age (years) (range) 66 45–85 60 37–82 57 22–87 56 22–87 58 22–87
Sex (% men) 57 60 12 44.44 67 69.07 32 54.24 79 63.71
Smoking status Currently (%) 30 31.58 11 40.74 64 65.98 23 38.98 75 60.48
Previously (%) 33 34.74 7 25.93 24 24.74 11 18.64 31 25.00
Never (%) 30 31.58 9 33.33 9 9.28 23 38.98 18 14.52
Unknown status (%) 2 2.11 0 0 0 0 2 3.39 0 0
AJCC/UICC staging I (IA and IB) (%) 11 11.58
II (IIA and IIB) (%) 29 30.53
III (%) 13 13.68
IV (%) 42 44.21
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Table 2 Hypermethylation frequencies for each gene in each group
Gene Pancreatic cancer (N = 95) Screened negative (N = 27) Chronic pancreatitis (N = 97) Acute pancreatitis (N = 59)
% n 95% CI % n 95% CI % n 95% CI % n 95% CI
ALX4 17.84 17 (10.78–27.10) 7.41 2 (0.91–24.29) 4.12 4 (1.13–10.22) 1.69 1 (0.04–9.09)
APC 82.11 78 (72.90–89.22) 44.44 12 (25.48–64.67) 54.64 53 (44.21–64.78) 67.80 40 (54.36–79.38)
BMP3 33.68 32 (24.31–44.11) 18.52 5 (6.30–38.08) 3.09 3 (0.64–8.77) 10.17 6 (3.82–20.8)
BNC1 35.79 34 (26.21–46.30) 7.41 2 (0.91–24.29) 5.15 5 (1.69–11.62) 6.78 4 (1.88–16.46)
BRCA1 10.53 10 (5.16–18.51) 14.81 4 (4.19–33.73) 7.22 7 (2.95–14.30) 32.20 19 (20.62–45.64)
CDKN2A 6.32 6 (2.35–13.24) 3.70 1 (0.09–18.97) 2.06 2 (0.25–7.25) 11.86 7 (4.91–22.93)
CDKN2B 12.63 12 (6.70–21.03) 7.41 2 (0.91–24.29) 5.15 5 (1.69–11.62) 11.86 7 (4.91–22.93)
CHFR 1.05 1 (0.03–5.73) 0 0 (0.00–12.77) 3.09 3 (0.64–8.77) 1.69 1 (0.04–9.09)
ESR1 77.89 74 (68.21–85.77) 62.96 17 (42.37–80.60) 60.82 59 (50.39–70.58) 76.27 45 (63.41–86.38)
EYA2 13.68 13 (7.49–22.26) 0 0 (0.00–12.77) 8.25 8 (3.63–15.61) 15.25 9 (7.22–26.99)
GSTP1 3.16 3 (0.66–8.95) 0 0 (0.00–12.77) 1.03 1 (0.03–5.61) 0 0 (0–6.06)
HIC1 15.79 15 (9.12–24.70) 0 0 (0.00–12.77) 6.19 6 (2.30–12.98) 6.78 4 (1.88–16.46)
MESTv2 78.95 75 (69.38–86.64) 44.44 12 (25.48–64.67) 58.76 57 (48.31–68.67) 66.10 39 (52.61–77.92)
MGMT 5.26 5 (1.73–11.86) 0 0 (0.00–12.77) 3.09 3 (0.64–8.77) 0 0 (0–6.06)
MLH1 14.74 14 (8.30–23.49) 22.22 6 (8.62–42.26) 7.22 7 (2.95–14.30) 28.81 17 (17.76–42.07)
NPTX2 74.74 71 (64.78–83.10) 62.96 17 (42.37–80.60) 42.27 41 (32.30–52.72) 49.15 29 (35.89–62.50)
NEUROG1 10.53 10 (5.16–18.51) 11.11 3 (2.35–29.16) 6.19 6 (2.30–12.98) 6.78 4 (1.88–16.46)
RARB 46.32 44 (36.02–56.85) 44.44 12 (25.48–64.67) 28.87 28 (20.11–38.95) 45.76 27 (32.72–59.24)
RASSF1A 42.11 40 (32.04–52.67) 14.81 4 (4.19–33.73) 11.34 11 (5.80–19.39) 16.95 10 (8.44–28.97)
SFRP1 44.21 42 (34.02–54.77) 25.93 7 (11.11–46.28) 17.53 17 (10.55–26.57) 18.64 11 (9.69–30.91)
SFRP2 38.95 37 (29.11–49.50) 18.52 5 (6.30–38.08) 25.77 25 (17.42–35.65) 6.78 4 (1.88–16.46)
SEPT9v2 14.74 14 (8.30–23.49) 0 0 (0.00–12.77) 3.09 3 (0.64–8.77) 1.69 1 (0.04–9.09)
SST 64.21 61 (53.72–73.79) 59.26 16 (38.80–77.61) 30.93 30 (21.93–41.12) 25.42 15 (14.98–38.44)
TFPI2 23.16 22 (15.12–32.94) 3.70 1 (0.09–18.97) 2.06 2 (0.25–7.25) 0 0 (0–6.06)
TAC1 58.95 56 (48.38–68.94) 14.81 4 (4.19–33.73) 35.05 34 (25.64–45.41) 25.42 15 (14.98–38.44)
VIM 3.16 3 (0.66–8.95) 0 0 (0.00–12.77) 0 0 (0–3.73) 0 0 (0–6.06)
WNT5A 8.42 8 (3.71–15.92) 0 0 (0.00–12.77) 1.03 1 (0.03–5.61) 0 0 (0–6.06)
PENK 2.11 2 (0.26–7.40) 0 0 (0.00–12.77) 0 0 (0–3.73) 0 0 (0–6.06)
Table 3 Mean number of hypermethylated genes in each group
Group N Mean number of methylated genes 95% CI p value
Pancreatic cancer 95 8.41 (7.62–9.20)
Control group 1; screened negative 27 4.89 (4.07–5.71)
Control group 2; chronic pancreatitis 97 4.34 (3.85–4.83)
Control group 3; acute pancreatitis 59 5.34 (4.77–5.91)
Control groups 1 + 2 124 4.46 (4.04–4.88) <0.0001a
Control groups 1 + 2 + 3 183 4.74 (4.40–5.08) <0.0001b
The means were compared as numerical data with nonparametric Wilcoxon rank sum test. p values less than 0.05 were considered statistically significant
aSignificant difference between patients with pancreatic cancer and control groups 1 + 2
bSignificant difference between patients with pancreatic cancer and control groups 1 + 2 + 3
CI confidential interval
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There was a highly significant difference (p < 0.001) be-
tween the cancer group and control groups 1 + 2 with re-
gard to hypermethylation frequency of ten genes (APC,
BMP3, BNC1, MESTv2, NPTX2, RASSF1A, SFRP1, SST,
TFPI2 and TAC1) (Table 4) and significant difference (p <
0.05) in seven other genes (ALX4, ESR1, HIC1, RARB,
SFRP2, SEPT9v2 and WNT5A) (Table 4). VIM and PENK
could not be evaluated by logistic regression, as none of the
patients in the control group had hypermethylation of these
two genes; however, chi-square test found significant differ-
ence between the cancer group and the control groups 1 +
2. Despite that, VIM and PENK were excluded from the fol-
lowing analysis because only very few cancer patients had
VIM or PENK hypermethylation. (Tables 2 and 4). There
was no significant difference in gender; consequently, this
variable was excluded from the subsequent analysis. Smok-
ing, however, was a preventive factor for cancer when com-
paring patients with pancreatic cancer and patients with
chronic pancreatitis. Smoking was therefore excluded from
the model because it is a known risk factor for cancer. By
stratifying the patients into groups according to age
(>65 years old, ≤65 years old), a statistically significant dif-
ference was found between the cancer group and control
groups 1 + 2. Consequently, patient age >65 years old was
included as a covariate in the multivariable logistic regres-
sion analysis.
All genes with an individual p value below 0.20 (20 genes
out of 28 examined genes) and patient age >65 were in-
cluded in the multivariable logistic regression model. Back-
ward stepwise selection was performed. Figure 2 illustrates
the stepwise elimination of variables from the model and
the corresponding AUC. The initial model (model 1) with
20 genes had an AUC of 0.87 (Fig. 2). Removing the 12
least significant genes from the model and leaving eight
genes (model 13; age >65, BMP3, RASSF1A, BNC1,
MESTv2, TFPI2, APC, SFRP1 and SFRP2) resulted in an
AUC of 0.86 (95% CI 0.81–0.91) (Figs. 2 and 3a). The mean
probability for having pancreatic adenocarcinoma was 0.67
(0.61–0.72) for cancer patients and 0.26 (0.22–0.29) for the
control groups 1 + 3. Model 13 was determined as the
model with the best performance (probability cut point of
0.50; sensitivity 76% and specificity 83%). There were no
statistically significant interactions between variables in
model 13. The model was well calibrated (p = 0.40) and had
an estimated optimism in AUC of 0.03.
Forty patients had stage I or II tumours. Model 13 had
an apparent AUC of 0.86 (95% CI 0.79–0.92) for stage I/II
tumours (probability cut point of 0.50; sensitivity 73% and
specificity 83%) (Fig. 3b) with an optimism in AUC of 0.06.
Discussion
We examined cell-free DNA promoter hypermethylation
of 28 genes in the plasma of a large cohort of patients with
pancreatic adenocarcinoma and compared it to different
Table 4 Variables included in the study
OR 95% CI p value AUC
ALX4 4.29 (1.62; 11.35) 0.0034 0.57
APC 4.16 (2.21; 7.84) 9.67 × 10−6 0.65
BMP3 7.37 (3.20; 16.95) 2.64 × 10−6 0.64
BNC1 9.32 (3.90; 22.25) 5.02 × 10−7 0.65
BRCA1 1.21 (0.49; 2.98) 0.6804 0.51
CDKN2A 2.27 (0.66; 11.17) 0.1652 0.52
CDKN2B 2.42 (0.91; 6.40) 0.0757 0.53
CHFR 0.43 (0.04; 4.19) 0.4668 0.51
ESR1 2.23 (1.22; 4.07) 0.0095 0.58
EYA2 2.30 (0.91; 5.80) 0.0778 0.54
GSTP1 4.01 (0.41; 39.18) 0.2323 0.51
HIC1 3.69 (1.37; 9.91) 0.0097 0.55
MESTv2 2.99 (1.63; 5.49) 0.0004 0.62
MGMT 2.24 (0.52; 9.62) 0.2778 0.51
MLH1 1.48 (0.66; 3.31) 0.3448 0.52
NPTX2 3.37 (1.88; 6.02) 4.34 × 10−5 0.64
NEUROG1 1.50 (0.59; 3.86) 0.3969 0.52
RARB 1.81 (1.04; 3.15) 0.0348 0.57
RASSF1A 5.28 (2.69; 10.39) 1.4 × 10−6 0.65
SFRP1 3.30 (1.81; 6.03) 0.0001 0.62
SFRP2 2.00 (1.12; 3.58) 0.0197 0.57
SEPT9v2 6.97 (1.94; 25.03) 0.0029 0.56
SST 3.04 (1.75; 5.30) 8.69 × 10−5 0.64
TFPI2 12.16 (3.51; 42.04) 7.96 × 10−5 0.60
TAC1 3.25 (1.86; 5.69) 3.63 × 10−5 0.64
VIM – – a –
WNT5A 11.31 (1.39; 92.08) 0.0234 0.54
PENK – – a –
Sex 0.85 (0.49; 1.48) 0.5750 0.52
Age 60 3.88 (2.17; 6.92) 4.58 × 10−6 0.66
Age 65 4.14 (2.33; 7.33) 1.14 × 10−6 0.67
Age 70 4.05 (2.04; 8.02) 6.06 × 10−5 0.62
All variables are analysed by simple logistic regression comparing the
pancreatic cancer group and control groups 1 + 2
Italic values indicate the genes, where there is significant difference (p < 0.05)
in hypermethylation frequency between the cancer group and control
groups 1 + 2
aVIM and PENK could not be evaluated by logistic regression because none of
the patients in the control group had hypermethylation of the two genes;
however, chi-square test found significant difference between the cancer
group and the control groups 1 + 2. Despite that, VIM and PENK were excluded
from the following analysis because only few cancer patients had VIM or
PENK hypermethylation
Control group 1; patients screened but negative for upper
gastrointestinal malignancy
Control group 3; patients with chronic pancreatitis
OR odds ratio, CI confidential interval, AUC area under the receiver operating
characteristic curve
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clinical relevant control groups. We designed the gene-
panel primary based on our literature review addressing
genes aberrantly methylated in pancreatic adenocarcin-
oma [16]. This approach was used, to evaluate the overall
diagnostic performance of genes which previously had
been examined separately as diagnostic markers for pan-
creatic cancer. The panel was composed of genes previ-
ously detected as hypermethylated in plasma/serum and
tumour tissue in relation to pancreatic adenocarcinoma
(BNC1 [17, 24, 25], NPTX2 [4, 24–26], PENK [4, 14, 25],
CDKN2A [4, 26, 27], RASSF1A [4, 24, 27], SFRP1 (SARP2)
[4, 25], APC [24, 27], BRCA1 [28, 29], CDKN2B [28, 30],
ESR1 [25, 28], MGMT [24, 28], MLH1 [28, 31] and RARB
[28, 32]), genes earlier found to be hypermethylated in
pancreatic juice or tumour tissue from patients with pan-
creatic adenocarcinoma (BMP3 [24], EYA2 [24], GSTP1
[29], HIC1 [25, 33], SFRP2 [24], TFPI2 [25], VIM [25],
NEUROG1 [24, 25], TAC1 [24, 25], CHFR [24] and
WNT5a [24, 25]) and genes found based on a pilot study
on cell-free DNA hypermethylation in colorectal adeno-
carcinoma (ALX4, MESTv2, SEPT9v2 and SST). To our
knowledge, this is the first study to examine cell-free
DNA hypermethylation in a wide selection of genes by
methylation-specific PCR in a large group of patients with
either malignant or benign pancreatic disease.
A statistically significant difference in the hypermethy-
lation status in 19 out of the 28 genes was found when
comparing pancreatic adenocarcinoma patients and a
control group containing patients screened, but negative
for pancreatic cancer, as well as in patients with chronic
pancreatitis. Cell-free DNA hypermethylation of BMP3,
MESTv2, SST, TFPI2, TAC1, ALX4, HIC1, SFRP2,
SEPT9v2 and WNT5A has not previously been described
in the literature in relation to pancreatic cancer. Yi et al.
described BNC1 hypermethylation to have a sensitivity
of 79% and a specificity of 89% when comparing pancre-
atic cancer and healthy individuals [17]. We found
BNC1 to be hypermethylated in only 36% of pancreatic
cancer patients with a specificity of 94%. Park et al. ex-
amined hypermethylation of a small gene panel (NPTX2,
RASSF1A, SFRP1, UCHL1, PENK and CDKN2A) by
methylation-specific PCR [4]. The gene panel could dif-
ferentiate pancreatic cancer from healthy controls; how-
ever, it was not able to discriminate benign and
malignant pancreatic disease.
Our study shows that cell-free DNA hypermethylation
is detectable in both malignant and benign pancreatic dis-
ease. However, patients with pancreatic adenocarcinoma
have a higher level of hypermethylated genes in plasma-
derived cell-free DNA. Consistent with previous studies,
our gene panel did not demonstrate a single gene, which
could be used as an individual diagnostic marker for pan-
creatic cancer. This result suggests that a larger gene panel
is needed to achieve sufficient accuracy [16]. We devel-
oped a diagnostic prediction model (age >65, BMP3,
RASSF1A, BNC1, MESTv2, TFPI2, APC, SFRP1 and
SFRP2), which was able to differentiate between pancre-
atic adenocarcinoma and a large control group of great
clinical relevance. The control group included patients












































































































Fig. 2 Stepwise selection of genes for the pancreatic cancer diagnostic prediction model. Stepwise selection of genes with the corresponding p
value and the area under the receiver operating characteristic curve (AUC). Model 13 was determined as the model with the best performance
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hospital with symptoms of pancreatic cancer. The AUC
was high, and the predictive value of our model is superior
to the predictive value of CA-19-9, which currently is the
only blood-based biomarker for pancreatic cancer. Par-
ticularly keeping in mind that CA-19-9 is highly
dependent on the Lewis blood group status of the pa-
tients. Only Lea+b− or Lea-b+ individuals are able to express
CA-19-9 but not Lea−b− individuals, which represent 5–
10% of the Caucasian population [34]. In a recent study,
CA-19-9 could differentiate patients with stage I–II pan-
creatic cancer from patients with chronic pancreatitis with
an AUC of 0.77 (sensitivity of 53% and a specificity of
92%) and pancreatic cancer patients from patients with
benign biliary obstruction with an AUC of only 0.65 [5].
Our study included patients with stage I–IV pancreatic
adenocarcinoma. It is most important to diagnose patients
with stage I and II disease as early detection at this stage
of the disease has the potential to improve the outcome of
surgery. We tested our model on stage I and II disease
and found an AUC of 0.86. This finding shows that the
performance of the prediction model is independent of
the cancer stage. DNA hypermethylation is detectable in
plasma even in an early stage of the disease and thereby
potentially usable as an early blood-based diagnostic
marker.
In order to further differentiate DNA hypermethyla-
tion related to malignant and benign pancreatic disease,
patients with acute pancreatitis were included. The aim
Fig. 3 Performance of model 13. a Stage I, II, III and IV pancreatic cancer. Model 13 (age >65, BMP3, RASSF1A, BNC1, MESTv2, TFPI2, APC, SFRP1,
SFRP2). AUC = 0.86 (probability cut point of 0.50; sensitivity 76% and specificity 83%).b Stage I and II pancreatic cancer. Model 13 (age >65, BMP3,
RASSF1A, BNC1, MESTv2, TFPI2, APC, SFRP1, SFRP2). AUC = 0.86 (probability cut point of 0.50; sensitivity 73% and specificity 83%)
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was to achieve a more basic understanding of hyper-
methylated DNA during the course of an acute pancre-
atic inflammatory reaction, which has not been
described earlier in literature. Our study shows that
DNA hypermethylation takes place during pathological
conditions in the pancreas including acute inflammation.
However, the changes are more pronounced in patients
with pancreatic adenocarcinoma.
Limitations
Our study has some limitations. The study was explora-
tory, showing training data only, which is known to pro-
duce an overestimation of the test performance due to
overfitting. Validation of the results in an independent
cohort is needed to substantiate the results.
Patients were not matched according to age, which
one should be aware of because epigenetic changes can
be a part of ageing [35]. To address this problem, we in-
corporated age as a covariate in our prediction model.
In addition, comparison of the performance of our
prediction model to CA-19-9 would have been relevant.
Unfortunately, this was impossible, as CA-19-9 was not
available on two thirds of the patients as this test was
first implemented in 2010 at our department.
The difference in sensitivity of the genes analysed in
our study and the sensitivity of genes examined in previ-
ous studies by others might be due to the use of differ-
ent primer sequences. Several methods are described for
methylation analysis which furthermore makes inter-
study comparison difficult [36].
We performed methylation-specific PCR, which is a
quantitative method using hemimethylated MEST tran-
script variant 1 as a reference gene [20]. However, our
study lacked sufficient power to conduct a quantitative
analysis. Therefore, we analysed hypermethylation as a
binary variable, which unfortunately results in loss of the
quantitative information.
At the end of the analyses, we discovered that the use
of UNG (Invitrogen) had a tendency to lower the sensi-
tivity compared to the use of COD UNG (ArcticZymes).
All our samples are analysed using UNG (Invitrogen) be-
cause it was not possible to repeat all analyses with
COD UNG (ArcticZymes) due to the lack of sample
material.
Strengths
However, the study also has several strengths. We tested
cell-free DNA hypermethylation of a broad gene panel
in the plasma from a large group of patients with pan-
creatic adenocarcinoma, all included prospectively and
consecutively, before the diagnostic workup and before
any treatment.
In addition, we included a large utmost relevant
group of control patients with either benign pancreatic
disease or with symptoms mimicking pancreatic cancer,
which all are patients clinically hard to differentiate
from patients with pancreatic cancer.
We performed methylation-specific PCR based on an
optimized bisulfite treatment protocol [20]. This method
has several advantages, due to a high recovery from sam-
ples with minute amounts of DNA (<0.01 ng/ml) and a
rapid deamination of DNA (less than 2 h) [20].
We developed a diagnostic prediction model for pan-
creatic adenocarcinoma with a high performance, inde-
pendent of cancer stage. In addition, the diagnostic
prediction model only had a modest optimism in per-
formance by intern validation.
Diagnostic biomarkers for pancreatic cancer are lack-
ing. We developed a diagnostic test, which has the great
advantage of being blood based and thereby minimally
invasive. In general, blood-based markers are of great
benefit to the patients compared to tissue-based
markers, as the latter entail a risk of complications. Fur-
thermore, due to the deep location of the pancreas in
the upper abdomen, biopsies may be difficult to obtain,
why blood-based markers are of utmost importance re-
garding pancreatic disease.
Conclusions
Our study demonstrates statistically significant differences
in cell-free DNA hypermethylation of several genes be-
tween malignant and benign pancreatic diseases. Patients
with pancreatic adenocarcinoma have a highly significant
number of hypermethylated genes compared to patients
with benign pancreatic diseases. A panel of hypermethy-
lated genes (BMP3, RASSF1A, BNC1, MESTv2, TFPI2,
APC, SFRP1 and SFRP2) are able to differentiate between
patients with pancreatic adenocarcinoma and a most rele-
vant control group. Based on our study, alterations in cell-
free DNA hypermethylation have the potential of serving
as blood-based biomarkers for the diagnosis of pancreatic
adenocarcinoma. External validation is however required
before the biomarker can be applied in daily clinical
practice.
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